Celgene files Hatch-Waxman suits against multiple generic pharmaceutical defendants over new dosage strengths of generic versions of Focalin XR®

Client(s) Celgene Corporation

Jones Day represents Celgene Corporation in separate Hatch-Waxman patent infringement actions against Teva Pharmaceuticals; Actavis South Atlantic; and IntelliPharmaCeutics over proposed new dosage strengths of generic versions of Celgene’s branded drug Focalin XR®.

Celgene Corporation et al. v. Teva Pharmaceuticals USA, Inc., Civil Action No. 2-11-cv-02356 (D.N.J.) (Judge Wigenton); Celgene Corporation et al. v. Actavis South Atlantic LLC, Civil Action No. 2-11-cv-02162 (D.N.J.) (Judge Wigenton); Celgene Corporation et al. v. IntelliPharmaCeutics Corporation, Civil Action No. 2-11-cv-01736 (D.N.J.) (Judge Wigenton)